| Literature DB >> 23965929 |
Jae-Sung Yi1, Jun Sub Park, Young-Mi Ham, Nga Nguyen, Na-Rae Lee, Jin Hong, Bong-Woo Kim, Hyun Lee, Chang-Seok Lee, Byung-Cheon Jeong, Hyun Kyu Song, Hana Cho, Yoon Ki Kim, Jae-Seon Lee, Kyong Soo Park, Haksub Shin, Inho Choi, Seung Hee Lee, Woo Jin Park, Shi-Young Park, Cheol Soo Choi, Peihui Lin, Malith Karunasiri, Tao Tan, Pu Duann, Hua Zhu, Jianjie Ma, Young-Gyu Ko.
Abstract
Mitsugumin 53 (MG53) negatively regulates skeletal myogenesis by targeting insulin receptor substrate 1 (IRS-1). Here, we show that MG53 is an ubiquitin E3 ligase that induces IRS-1 ubiquitination with the help of an E2-conjugating enzyme, UBE2H. Molecular manipulations that disrupt the E3-ligase function of MG53 abolish IRS-1 ubiquitination and enhance skeletal myogenesis. Skeletal muscles derived from the MG53-/- mice show an elevated IRS-1 level with enhanced insulin signalling, which protects the MG53-/- mice from developing insulin resistance when challenged with a high-fat/high-sucrose diet. Muscle samples derived from human diabetic patients and mice with insulin resistance show normal expression of MG53, indicating that altered MG53 expression does not serve as a causative factor for the development of metabolic disorders. Thus, therapeutic interventions that target the interaction between MG53 and IRS-1 may be a novel approach for the treatment of metabolic diseases that are associated with insulin resistance.Entities:
Mesh:
Substances:
Year: 2013 PMID: 23965929 PMCID: PMC3941707 DOI: 10.1038/ncomms3354
Source DB: PubMed Journal: Nat Commun ISSN: 2041-1723 Impact factor: 14.919